GBM immunotherapy: Exploring molecular and clinical frontiers
MK Ghosh, S Kumar, S Begam, S Ghosh, M Basu - Life Sciences, 2024 - Elsevier
GBM is the most common, aggressive, and intracranial primary brain tumor; it originates from
the glial progenitor cells, has poor overall survival (OS), and has limited treatment options. In …
the glial progenitor cells, has poor overall survival (OS), and has limited treatment options. In …
Pericytes Are Immunoregulatory Cells in Glioma Genesis and Progression
M Martinez-Morga, D Garrigos… - International Journal of …, 2024 - mdpi.com
Vascular co-option is a consequence of the direct interaction between perivascular cells,
known as pericytes (PCs), and glioblastoma multiforme (GBM) cells (GBMcs). This process …
known as pericytes (PCs), and glioblastoma multiforme (GBM) cells (GBMcs). This process …
Targeted opening of the blood–brain barrier facilitates doxorubicin/anti-PD-1-based chemoimmunotherapy of glioblastoma
JG Pol, M Lizarralde-Guerrero, A Checcoli… - …, 2024 - Taylor & Francis
Doxorubicin is a prototypical inducer of immunogenic cell death (ICD) that sensitizes to
subsequent immunotherapy by PD-1 blockade. However, this systemic drug combination …
subsequent immunotherapy by PD-1 blockade. However, this systemic drug combination …
Locoregional delivery of chimeric antigen receptor-T cells: Breaking the spell in glioblastoma?
M Geurts, M Preusser - Neuro-oncology, 2024 - academic.oup.com
Breaking News Editorial 1178 were not only detectable in the cerebrospinal fluid (CSF) and
tumor cavity fluid for> 7 days in a subset of patients, but were also able to traffic to the …
tumor cavity fluid for> 7 days in a subset of patients, but were also able to traffic to the …